Grand Rapids, Michigan
Phase 3 cancer trials in Grand Rapids, MI
55 Phase 3 cancer studies are recruiting participants at sites in Grand Rapids as of November 18, 2026, according to ClinicalTrials.gov. Phase 3 Cancer Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Grand Rapids at a glance
- 55 studies are recruiting at a site in Grand Rapids.
- By phase: Phase 2/3 (5), Phase 3 (50).
- By sponsor: industry (28), university, hospital or other (19), government (8).
- By research area: Breast Cancer (14), Lung Cancer (14), Lymphoma (13), Prostate Cancer (7), Pancreatic Cancer (4), Melanoma (3).
- Most recent update to one of these records: November 18, 2026.
Breast cancer studies recruiting in Grand Rapids
Basic details from each study's public record (the 30 most recently updated of 55). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Cancer & Hematology Centers of Western Michigan ( Site 0026)
- Registry record
- NCT06841354 · updated
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- LeonaBio
- Study site
- Cancer and Hematology Centers of Western Michigan
- Registry record
- NCT05696626 · updated
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- SWOG Cancer Research Network
- Study site
- Spectrum Health at Butterworth Campus
- Registry record
- NCT03418961 · updated
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital · Trinity Health Grand Rapids Hospital
- Registry record
- NCT06058377 · updated
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- Cancer & Hematology Centers of Western Michigan
- Registry record
- NCT07413939 · updated
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Gilead Sciences
- Study site
- Cancer and Hematology Centers of Western Michigan
- Registry record
- NCT05633654 · updated
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Phase 3
- Ages 18 to 60
- Female participants
- Sponsor
- NRG Oncology
- Study sites
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital · Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital · Trinity Health Grand Rapids Hospital
- Registry record
- NCT05879926 · updated
E-Mindfulness Approaches for Living After Breast Cancer
- Phase 3
- Ages 18 to 50
- All sexes
- Sponsor
- NRG Oncology
- Study site
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
- Registry record
- NCT06748222 · updated
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- Cancer & Hematology Centers of Western Michigan
- Registry record
- NCT06790693 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Grand Rapids, MI on ClinicalTrials.gov.
Lung cancer studies recruiting in Grand Rapids
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital · Trinity Health Grand Rapids Hospital
- Registry record
- NCT06498635 · updated
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital · Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
- Registry record
- NCT07388524 · updated
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital · Trinity Health Grand Rapids Hospital
- Registry record
- NCT04267848 · updated
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- Phase 3
- Ages 70 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital · Trinity Health Grand Rapids Hospital
- Registry record
- NCT06096844 · updated
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Pfizer
- Study sites
- Corewell Health · Corewell Health - Butterworth Hospital · Corewell Health - Lemmen Holton Cancer Pavilion
- Registry record
- NCT06758401 · updated
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- The Cancer & Hematology Centers
- Registry record
- NCT06119581 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Grand Rapids, MI on ClinicalTrials.gov.
Prostate cancer studies recruiting in Grand Rapids
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study site
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
- Registry record
- NCT07200830 · updated
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Cancer and Hematology Centers of Western Michigan ( Site 0015)
- Registry record
- NCT06925737 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Grand Rapids, MI on ClinicalTrials.gov.
Melanoma studies recruiting in Grand Rapids
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
- Phase 3
- Ages 75 and older
- All sexes
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Study sites
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital · Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
- Registry record
- NCT07068074 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Grand Rapids, MI on ClinicalTrials.gov.
Lymphoma studies recruiting in Grand Rapids
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital · Trinity Health Grand Rapids Hospital
- Registry record
- NCT06337318 · updated
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Corewell Health-Lemmon Holton Cancer Pavilion ( Site 0011)
- Registry record
- NCT06136559 · updated
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Corewell Health ( Site 0130)
- Registry record
- NCT06717347 · updated
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital · Trinity Health Grand Rapids Hospital
- Registry record
- NCT04269902 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital · Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital · Trinity Health Grand Rapids Hospital
- Registry record
- NCT05675410 · updated
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- BeOne Medicines
- Study site
- Corewell Health the Michigan Cancer Consortium
- Registry record
- NCT06846671 · updated
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Regeneron Pharmaceuticals
- Study site
- Cancer and Hematology Centers of Western Michigan
- Registry record
- NCT06091865 · updated
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Phase 3
- Ages 18 to 39
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study sites
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital · Trinity Health Grand Rapids Hospital
- Registry record
- NCT03150693 · updated
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Corewell Health ( Site 0162)
- Registry record
- NCT05139017 · updated
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
- Phase 3
- Ages 12 and older
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study sites
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital · Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
- Registry record
- NCT07215910 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Grand Rapids, MI on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in Grand Rapids
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Incyte Corporation
- Study site
- Investigative Site US078
- Registry record
- NCT07522073 · updated
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- Exelixis
- Study site
- The Cancer and Hematology Centers
- Registry record
- NCT06943755 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Grand Rapids, MI on ClinicalTrials.gov.
Ask about studies near Grand Rapids
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in Michigan
All Michigan locations
116 studies recruiting across 59 cities.
Detroit
66 studies recruiting.
Ann Arbor
46 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 3, including combined Phase 2/3, as each study is coded in the registry.
Phase 3 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections